Asosiy kontentga oʻtish
Maqola

Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by <i>Nanoparticle Albumin-Bound</i> –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

Diana CirsteaCellworks Group, Inc., Saratoga, CaliforniaTeru HideshimaCellworks Group, Inc., Saratoga, CaliforniaScott J. RodigAuthors' Affiliations: 1Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women's Hospital; 3MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 4Abraxis Bioscience LLC, Los Angeles, California; 5Keryx Biopharmaceuticals, Inc., New York, New York; and 6Cellworks Group, Inc., Saratoga, CaliforniaLoredana SantoCellworks Group, Inc., Saratoga, CaliforniaSamantha PozziAuthors' Affiliations: 1Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women's Hospital; 3MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 4Abraxis Bioscience LLC, Los Angeles, California; 5Keryx Biopharmaceuticals, Inc., New York, New York; and 6Cellworks Group, Inc., Saratoga, CaliforniaSonia ValletKeryx Biopharmaceuticals, Inc., New York, New YorkHiroshi IkedaAuthors' Affiliations: 1Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women's Hospital; 3MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 4Abraxis Bioscience LLC, Los Angeles, California; 5Keryx Biopharmaceuticals, Inc., New York, New York; and 6Cellworks Group, Inc., Saratoga, CaliforniaGiulia PerroneAuthors' Affiliations: 1Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women's Hospital; 3MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 4Abraxis Bioscience LLC, Los Angeles, California; 5Keryx Biopharmaceuticals, Inc., New York, New York; and 6Cellworks Group, Inc., Saratoga, CaliforniaGüllü GörgünAuthors' Affiliations: 1Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women's Hospital; 3MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 4Abraxis Bioscience LLC, Los Angeles, California; 5Keryx Biopharmaceuticals, Inc., New York, New York; and 6Cellworks Group, Inc., Saratoga, CaliforniaKishan PatelAuthors' Affiliations: 1Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women's Hospital; 3MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 4Abraxis Bioscience LLC, Los Angeles, California; 5Keryx Biopharmaceuticals, Inc., New York, New York; and 6Cellworks Group, Inc., Saratoga, CaliforniaNeil DesaiAuthors' Affiliations: 1Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women's Hospital; 3MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 4Abraxis Bioscience LLC, Los Angeles, California; 5Keryx Biopharmaceuticals, Inc., New York, New York; and 6Cellworks Group, Inc., Saratoga, CaliforniaPeter SportelliAuthors' Affiliations: 1Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women's Hospital; 3MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 4Abraxis Bioscience LLC, Los Angeles, California; 5Keryx Biopharmaceuticals, Inc., New York, New York; and 6Cellworks Group, Inc., Saratoga, CaliforniaShweta KapoorCellworks Group, Inc., Saratoga, CaliforniaShireen ValiAuthors' Affiliations: 1Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women's Hospital; 3MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 4Abraxis Bioscience LLC, Los Angeles, California; 5Keryx Biopharmaceuticals, Inc., New York, New York; and 6Cellworks Group, Inc., Saratoga, CaliforniaSiddhartha MukherjeeKeryx Biopharmaceuticals, Inc., New York, New YorkNikhil C. MunshiAuthors' Affiliations: 1Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women's Hospital; 3MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 4Abraxis Bioscience LLC, Los Angeles, California; 5Keryx Biopharmaceuticals, Inc., New York, New York; and 6Cellworks Group, Inc., Saratoga, CaliforniaKenneth C. AndersonCellworks Group, Inc., Saratoga, CaliforniaNoopur RajeDepartment of Pathology, Brigham and Women's Hospital
2010en
ABI

Annotatsiya

The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway mediates multiple myeloma (MM) cell proliferation, survival, and development of drug resistance, underscoring the role of mTOR inhibitors, such as rapamycin, with potential anti-MM activity. However, recent data show a positive feedback loop from mTOR/S6K1 to Akt, whereby Akt activation confers resistance to mTOR inhibitors. We confirmed that suppression of mTOR signaling in MM cells by rapamycin was associated with upregulation of Akt phosphorylation. We hypothesized that inhibiting this positive feedback by a potent Akt inhibitor perifosine would augment rapamycin-induced cytotoxicity in MM cells. Perifosine inhibited rapamycin-induced phosphorylated Akt, resulting in enhanced cytotoxicity in MM.1S cells even in the presence of interleukin-6, insulin-like growth factor-I, or bone marrow stromal cells. Moreover, rapamycin-induced autophagy in MM.1S MM cells, as evidenced by electron microscopy and immunocytochemistry, was augmented by perifosine. Combination therapy increased apoptosis detected by Annexin V/propidium iodide analysis and caspase/poly(ADP-ribose) polymerase cleavage. Importantly, in vivo antitumor activity and prolongation of survival in a MM mouse xenograft model after treatment was enhanced with combination of nanoparticle albumin-bound-rapamycin and perifosine. Utilizing the in silico predictive analysis, we confirmed our experimental findings of this drug combination on PI3K, Akt, mTOR kinases, and the caspases. Our data suggest that mutual suppression of the PI3K/Akt/mTOR pathway by rapamycin and perifosine combination induces synergistic MM cell cytotoxicity, providing the rationale for clinical trials in patients with relapsed/refractory MM. Mol Cancer Ther; 9(4); 963-75. (c)2010 AACR.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba